Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P160024/S014

LifeStream Balloon Expandable Vascular Covered Stent

Bard Peripheral Vascular, Inc. · Decision date Sep 29, 2025

FDA DECISIONP160024/S014

What did the FDA decide?

FDA records P160024/S014 as a supplement to PMA P160024, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 29, 2025.

FDA approval order statement

an additional manufacturing facility for the stent covering process
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Sep 29, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P160024/S014
Regulatory pathway
PMA supplement
Product code
PRL
Decision code
OK30
Decision date
Sep 29, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Iliac covered stent, arterial.

Product code
PRL
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P160024/S014 received

    Application receipt date recorded by FDA.

  2. P160024/S014 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P160024. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code PRL

Product / regulatory recordCompanyPathwayDecision dateSource
W. L. Gore & Associates, Inc.PMA supplementOct 8, 2026FDA
W. L. Gore & Associates, Inc.PMA supplementJun 16, 2026FDA
Atrium Medical Corp.PMA supplementMay 13, 2026FDA
W. L. Gore & Associates, Inc.PMA supplementFeb 5, 2026FDA
Atrium Medical Corp.PMA supplementDec 22, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Bard Peripheral Vascular, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1625 W. 3rd St., Tempe, AZ, 85281

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records